Fierce Biotech News & Reports
Oct 28, 2024 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · Viking Therapeutics’ dual GLP-1 and GIP agonist produced weight loss of up to 14.7% after 13 weeks of treatment in data released in February. The results were competitive to the Big Pharma ...
MedTech | Fierce Biotech
Oct 28, 2024 · What medtech CEOs are saying about Trump’s potential tariffs. If President-elect Donald Trump implements his plans for blanket 10% to 20% tariffs on imported goods—and steeper rates for ...
Biotech | Fierce Biotech
Nov 1, 2024 · Genentech axes Nykode cancer vaccine deal. The decision by Roche's Genentech is "a result of an assessment of their overall portfolio of activities,” Nykode's CEO said on a webcast. Gabrielle ...
AstraZeneca's '2.0' cancer pipeline built on bispecifics - Fierce …
Oct 24, 2023 · AstraZeneca believes it has a unique approach, in part due to its proprietary bispecific platform, which has allowed the pharma to introduce fewer mutations that are needed to create the correct ...
JPM24 opens with ADCs the hottest ticket in San Francisco
Jan 8, 2024 · ADCs have been all the rage this fall. J.P. Morgan says there have actually been fewer total—but the deals that did happen were huge. There was $4.6 billion in upfront cash and equity doled out ...
Altos bursts out of stealth with $3B, a dream team C-suite and a …
Jan 19, 2022 · Altos Labs just redefined big. RELATED: Barron quits GSK to take CEO post at $3B biotech startup The team will use $3 billion in capital committed by investors including Arch Venture Partners to ...
FDA OKs Neuralace's nerve stimulation tech for diabetes ...
Jan 11, 2024 · Neuralace weaves new diabetic neuropathy indication into noninvasive nerve stimulation tech. In mid-2021, after a decade of R&D, Neuralace Medical earned FDA clearance for its Axon Therapy, a ...
CRO industry to face heightened expectations in 2024: report
Jan 4, 2024 · Speaking to diversity in clinical trials, WCG notes that the FDA recently began requiring pharmaceutical companies to include a diversity action plan with their requests for phase 3 or pivotal ...
New AI drug discovery powerhouse Xaira rises with $1B in ...
Apr 24, 2024 · The company emerged Tuesday with $1 billion in committed funding—that’s billion with a B—incubated by Arch Venture Partners and Foresite Labs with none other than Marc Tessier-Lavigne, Ph.D ...